Press Conference Arthritic Disease Abs 1451 Ologhobo & colleagues examined impact of virtual exercise program in individuals w/ MSK conditions Members reported decrease in - Pain - Pain interference - Fatigue - Stiffness #ACR21 @RheumNow https://t.co/T5qdlLEYZ0

Top Influencers of #acr21: @ACRheum @rheum_cat @RheumNow @CreakyJoints @RichardPAConway @KDAO2011 @alhkim More 📊 https://t.co/vyMAwjKbqC

• #acr21 - ACR Convergence 2021 - Social Media Analytics and Transcripts

*️⃣Abst#1800 observed that a changing pattern of purine, lipid, & amino acid metabolites occurred during transition from PsO to PsA. *️⃣Compared to pts w/ Pso that didn't progress to PsA, those that progressed had elevated levels of guanine! Potential biomarkers? #ACR21 @RheumNow https://t.co/iQh1ZapDMB

Dementia is ⬆️in #RheumatoidArthritis says Elena Myasoedva but #RA has more DM &CV disease which ⬆️dementia. Need to separate vascular dementia from Alzheimer’s. When I trained we thought less dementia in RA -likely not true. More work is coming. 9T213 aging hub #ACR21 @RheumNow

Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept: ⭐️Seropositivity ⭐️no prior bMDARD use ⭐️low HAQ-DI ⭐️low BMI Abst#1228 #ACR21 @Rheumnow https://t.co/NvJoSWScZs

⭐️Immune phenotyping of 45 patients with Pso and 41 PsA pts showed a number of cell subsets significantly different in Pso vs PsA ⭐️Future possibility of using a combination of selected immune cell subsets as a method for detecting PsA in Pso pts Abst#1774 #ACR21 @Rheumnow https://t.co/ER1MPOvMa6

#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx

• Additional Heterologous versus Homologous Booster Vaccination in Immunosuppress…

Abst#1774 identified a blood-based immune profile with a machine-learning approach that discriminates PsA from Pso. ➡️↑ proportions of differentiated CD4+CD196+CD183–CD194+ and CD4+CD196–CD183–CD194+ T-cells in PsA #ACR21 @RheumNow https://t.co/64uhJCd2qo

Fibromyalgianess Glucocorticoid Persistence in RA Patients: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0120 presented at the #ACR21 annual meeting. https://t.co/9yOM5rSARv https://t.co/Gq2YxbxkmM

• https://bit.ly/3mU8Voe

RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by #RheumNow & its Faculty.

Great work from #CATCH cohort. Yes I am biased. @earlyarthritis #ACR21 abst#1661 @RheumNow https://t.co/hogyNEQiWM

• Akhil Sood MD on Twitter: "Abst 1661
Scheir & colleagues identifie…

#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK

• Olga Petryna on Twitter: "Abst1773 #ACR21 @rheumnow guselkumab outperforms…

COVID 19 Poster Review Abst 0197 Haibel & colleagues performed open label study on IL-1/IL-6 inhibitor combo - Majority avoided mechanical ventilation (25/31) - 2 pts died while on ECMO - CT Chest findings improved 1 month after treatment #ACR21 @RheumNow https://t.co/CIJR1Tx8St

Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept: ⭐️Seropositivity ⭐️no prior bMDARD use ⭐️low HAQ-DI ⭐️low BMI Abst#1228 @ACR21 @Rheumnow https://t.co/LRd1HVbm5B